This study is in progress, not accepting new patients

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

a study on Preterm Birth

Summary

Eligibility
for females ages 18-55 (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion

Description

Summary

Prospective multicenter observational study to further develop and validate a preterm birth risk predictor, using a preterm cutoff at 37 0/7 weeks gestation and at 35 0/7 weeks gestation. A single maternal peripheral blood sample will be collected for analysis. Data related to potential risk factors for preterm birth will be obtained through maternal interview and review of medical records. Subjects will be followed through the delivery process to assess the course of pregnancy, labor, and to document any related maternal complications. Neonatal outcomes will be gathered from the medical record for up to 28 days of life or discharge, whichever occurs first.

Keywords

Preterm Birth proteomics pregnancy biomarkers Premature Birth

Eligibility

You can join if…

Open to females ages 18-55

  • Subject is 18 years of age or older
  • Subject has singleton gestation
  • Subject is able to provide consent
  • Gestational age is confirmed by a documented crown rump length on an ultrasound performed at the study site within 6 0/7 weeks and 13 6/7 weeks gestation (first trimester)
  • Subject has no signs and/or symptoms of preterm labor and has intact membranes
  • Investigator believes subject is willing to comply with study visits and procedures
  • Investigator believes the subject's delivery data will be available within 15 business days from delivery, and neonatal data will be available for data collection purposes within 15 business days from discharge

You CAN'T join if...

  • The subject has a planned cesarean section or induction of labor prior to 370/7 weeks of gestation
  • The subject has a planned cerclage placement for the current pregnancy
  • There is a known or suspected fetal anomaly or chromosomal abnormality
  • The subject has had a blood transfusion during the current pregnancy
  • The subject has known elevated bilirubin levels (hyperbilirubinemia)
  • The subject has taken or plans to take any of the following medications during the current pregnancy:
  • Progesterone or progesterone-derivative medication after 13 6/7 weeks gestation
  • Enoxaparin, heparin, heparin sodium, low molecular weight heparin after first day of last menstrual period
  • The subject has participated in, or plans to participate in, an interventional treatment study during the current pregnancy
  • The current pregnancy was previously a multiple gestation that is now a single fetus due to reduction, vanishing twin, etc.

Locations

  • University of California, Irvine Medical Center
    Orange California 92868 United States
  • UC San Diego Health
    San Diego California 92103 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sera Prognostics, Inc.
ID
NCT02787213
Study Type
Observational
Last Updated